A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

Study Identifier:
382-201-00033
ClinicalTrials.gov Identifier:
NCT07767903
EudraCT Identifier:
N/A
EU CT ID:
2026-526034-10-00
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
844-687-8522 or [email protected]
Recruiting
Subscribe to Updates

Study Details

Medical Condition
  • Anxiety
Study Drug
  • Drug: SEP-363856
  • Drug: Placebo
Date
Aug 2026 - Oct 2028
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Inclusion and Exclusion Criteria
  • Key Inclusion Criteria
  • Male or female participants at least 18 years of age at the time of informed consent
  • Primary diagnosis of GAD per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by Mini-International Neuropsychiatric Interview (MINI) and clinical psychiatric evaluation
  • Body Mass Index (BMI) 18-40 kilograms per square meter (kg/m\^2)
  • Participant is willing and able to comply with study procedures and visit schedule
  • Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests and able to comply with study procedures
  • Willing and able to discontinue prohibited medications/therapies per protocol
  • (i ) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception (ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
  • Willing and able to discontinue prohibited medications/therapies per protocol
  • Key Exclusion Criteria
  • Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the primary focus of treatment within 12 months prior to screening
  • Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
  • Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder, borderline or antisocial personality disorder)
  • Significant suicide risk e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale \[C-SSRS\] or MADRS)
  • Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines, investigational treatments)
  • Prior exposure to restricted treatments
  • Pregnant or breastfeeding females
  • Participation in another investigational study within 180 days (or more than \[\>\] 1 trial in last year)
  • Known history of human immunodeficiency virus seropositivity, hepatitis B or C

Protocol Summary

This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day \[mg/day\]) to placebo over an 8-week double-blind treatment period in adults with generalized anxiety disorder (GAD).

Study Locations

Location
Status
Location
Lumina Clinical Research Center
Cherry Hill, New Jersey, United States, 08002
Status
Recruiting
Location
Basil Clinical
Jamaica, New York, United States, 11413
Status
Recruiting
© 2025 Otsuka America Pharmaceutical, Inc.
All rights reserved.

July 2025 01US25EUC0279

Requirements information
  • Key Inclusion Criteria
  • Male or female participants at least 18 years of age at the time of informed consent
  • Primary diagnosis of GAD per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by Mini-International Neuropsychiatric Interview (MINI) and clinical psychiatric evaluation
  • Body Mass Index (BMI) 18-40 kilograms per square meter (kg/m\^2)
  • Participant is willing and able to comply with study procedures and visit schedule
  • Medically stable as determined by medical history, physical exam, vital signs, and laboratory tests and able to comply with study procedures
  • Willing and able to discontinue prohibited medications/therapies per protocol
  • (i ) Females of childbearing potential: negative pregnancy test and agreement to use acceptable contraception (ii) Males: agreement to follow protocol-defined contraception and reproductive restrictions
  • Willing and able to discontinue prohibited medications/therapies per protocol
  • Key Exclusion Criteria
  • Current DSM-5 diagnosis of major depressive episode, post traumatic stress disorder (PTSD), or any psychiatric disorder other than GAD that was the primary focus of treatment within 12 months prior to screening
  • Substance use disorder (excluding nicotine/caffeine) within 12 months prior to screening
  • Lifetime history of certain psychiatric disorders (e.g., schizophrenia spectrum disorders, bipolar disorder, obsessive-compulsive disorder, borderline or antisocial personality disorder)
  • Significant suicide risk e.g., recent suicidal behavior/ideation per Columbia-Suicide Severity Rating Scale \[C-SSRS\] or MADRS)
  • Use of prohibited medications/therapies within protocol-defined timeframes (e.g., certain antipsychotics, mood stabilizers, benzodiazepines, investigational treatments)
  • Prior exposure to restricted treatments
  • Pregnant or breastfeeding females
  • Participation in another investigational study within 180 days (or more than \[\>\] 1 trial in last year)
  • Known history of human immunodeficiency virus seropositivity, hepatitis B or C

We defy limitation,

so that others can too.

Follow Us
OAPI and OPDC Locations

508 Carnegie Center Dr,

Princeton, NJ 08540, United States

Phone 609-524-6788

2440 Research Blvd,

Rockville, MD 20850, United States

Phone 301-424-9055

3956 Point Eden Way

Hayward, CA 94545, United States

Phone 800-562-3974